The company is aggressively expanding its oncology pipeline with ongoing Phase 3 trials for sigvotatug vedotin in lung cancer and planned studies in other cancers. A Phase 3 readout for multiple ...
Among the new phase 3 starts are CDK4 inhibitor atirmociclib as a second-line therapy for hormone receptor-positive metastatic breast cancer, IB6-directed ADC sigvotatug vedotin for non-small cell ...
The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback